Antibody selection for antibody-drug conjugates (ADCs) has traditionally depended on its internalization into the target cell， although ADC efficacy also relies on recycling of the receptor-ADC complex， endo-lysosomal trafficking， and subsequent linker/antibody proteolysis. In this study， we observed that a bispecific anti-murine platelet-derived growth factor receptor beta (mPDGFRβ) x cotinine single-chain variable fragment (scFv)-kappa constant region (C)-scFv fusion protein and cotinine-duocarmycin can form an ADC-like complex to induce cytotoxicity against mPDGFRβ expressing cells. Multiple anti-mPDGFRβ antibody candidates can be produced in this bispecific scFv-C-scFv fusion protein format and tested for their ability to deliver cotinine-conjugated cytotoxic drugs， thus providing an improved approach for antibody selection in ADC development.